Plex Pharmaceuticals, Inc.
San Diego, CA · Biotech · Acquired
Small molecule protease inhibitors targeting flavivirus NS2B-NS3 protease for treatment of dengue, Zika, and West Nile virus infections
plexpharma.com →- Grants
- $4.2M
- 10 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 21
- 2 granted · 19 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201420152016201720182019202020212022
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Development of Flavivirus Antivirals Targeting Dengue Virus and WNV Protease | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Small molecule activators of alpha-crystallin for non-surgical treatment of cataracts | $162,399 | |
| Federal grant | Department of Health and Human Services · Phase I · Small molecule activators of alpha crystallin for non surgical treatment of cataracts | $299,173 | |
| Federal grant | Department of Health and Human Services · Phase I · Small molecule activators of alpha-crystallin for non-surgical treatment of cataracts | $136,774 | |
| Federal grant | Department of Health and Human Services · Phase I · Discovery and Development of Broad-spectrum Protease Inhibitors of Flaviviruses of Significant Public Health Threats | $600,000 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · Advancing CAP4196 into in vivo Proof of Concept Translational Studies | $1,311,882 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Re-purposing the small-molecule drug, tafamidis (CAP4349) for the non-surgical treatment of cataracts | $298,590 | |
| Federal grant | Department of Health and Human Services · Phase I · Discovery and Development of Broad-spectrum Protease Inhibitors of Flaviviruses of Significant Public Health Threats | $300,000 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Re-purposing the small-molecule drug, tafamidis (CAP4349) for the non-surgical treatment of cataracts | $149,295 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · Advancing CAP4196 into in vivo Proof of Concept Translational Studies | $648,986 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1950 | SCALED MICROBIOMICS, LLC | — | — |
| 1951 | RYLTI, LLC | — | $2.3M |
| 1952 | Cargo Therapeutics | — | $69M |
| 1953 | Plex Pharmaceuticals, Inc. | — | — |
| 1954 | Caring Brands, Inc. | — | $1.8M |
| 1955 | KIBIO INC. | — | — |
| 1956 | SAROS THERAPEUTICS INC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Dual Acting FKBP12 And FKBP52 Inhibitorsgranted
- Pharmacological Agents For Treating Ophthalmic Diseasesapplication
- Pharmacological Agents For Preventing And Treating Cataracts And Presbyopia Eye Diseasesapplication
- Dual Acting FKBP12 And FKBP52 Inhibitorsgranted
- Pharmacological Agents For Treating Conditions Of The Eyeapplication
- Pharmacological Agents For Treating Protein Aggregation Diseases Of The Eyeapplication
- Pharmacological Agents For Treating Conditions Of The Eyeapplication
- Pharmacological Agents For Treating Ophthalmic Diseasesapplication
- Pharmacological Agents For Preventing Treating Cataracts And Presbyopia Eye Diseasesapplication
- Pharmacological Agents For Treating Myopiaapplication
- Pharmacological Agents For Treating Protein Aggregation Diseases Of The Eyeapplication
- Dual Acting FKBP12 And FKBP52 Inhibitorsapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.